Burzynski Research Institute Inc BZYR:OTCPK

RT Quote | Exchange | USD
Last | 09/22/22 EDT
0.0346UNCH (UNCH)
52 week range
0.01 - 0.05
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0346
  • 52 Week High0.05
  • 52 Week High Date04/01/22
  • 52 Week Low0.01
  • 52 Week Low Date12/31/21

Key Stats

  • Market Cap4.54M
  • Shares Out131.45M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change187.92

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0346
  • 52 Week High0.05
  • 52 Week High Date04/01/22
  • 52 Week Low0.01
  • 52 Week Low Date12/31/21
  • Market Cap4.54M
  • Shares Out131.45M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change187.92

RATIOS/PROFITABILITY

  • EPS (TTM)-0.01
  • P/E (TTM)-5.10
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-892,120.00
  • ROE (TTM)-
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Burzynski Research Institute Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion, and sale of certain medical chemical compounds. The chemical compounds are composed of growth-inhibiting peptides, amino acid derivatives, and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various...
Stanislaw Burzynski M.D., Ph.D.
Chairman of the Board, President
Tomasz Janicki M.D.
Vice President - Clinical Trials
Address
12000 Richmond Ave
Houston, TX
77082
United States